Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03952325
Title Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.

triple-receptor negative breast cancer

Her2-receptor negative breast cancer


Pembrolizumab + Tesetaxel

Nivolumab + Tesetaxel


Atezolizumab + Tesetaxel

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.